CaIPLA2 Polyclonal Antibody, PerCP Conjugated
Applications
Predicted Reactivity
| Overview | |
| Catalog # | bs-6709R-PerCP-100uL |
| Product Name | CaIPLA2 Polyclonal Antibody, PerCP Conjugated |
| Applications |
WB
IF(IHC-P)
IF(IHC-F)
IF(ICC)
|
| Predicted Reactivity | Human, Mouse, Rat, Dog, Cow, Sheep, Pig, Rabbit |
| Specifications | |
| Conjugation | PerCP |
| Host | Rabbit |
| Source | KLH conjugated synthetic peptide derived from human CaI-PLA2/PLA2G6 |
| Clonality | Polyclonal |
| Isotype | IgG |
| Concentration | 1ug/ul |
| Purification | Purified by Protein A. |
| Storage Buffer | Aqueous buffered solution containing 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Storage Condition | Store at -20C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target | |
| Gene ID | 8398 |
| Swiss Prot | O60733 |
| Subcellular location | Cytoplasm, Cell membrane |
| Synonyms | GVI; PLA2; INAD1; NBIA2; iPLA2; NBIA2A; NBIA2B; PARK14; PNPLA9; CaI-PLA2; IPLA2-VIA; iPLA2beta; 85/88 kDa calcium-independent phospholipase A2; Group VI phospholipase A2; GVI PLA2; Intracellular membrane-associated calcium-independent phospholipase A2 beta; iPLA2-beta; Patatin-like phospholipase domain-containing protein 9; PLA2G6; PLPLA9 |
| Background | Catalyzes the release of fatty acids from phospholipids. It has been implicated in normal phospholipid remodeling, nitric oxide-induced or vasopressin-induced arachidonic acid release and in leukotriene and prostaglandin production. May participate in fas mediated apoptosis and in regulating transmembrane ion flux in glucose-stimulated B-cells. Has a role in cardiolipin (CL) deacylation. Required for both speed and directionality of monocyte MCP1/CCL2-induced chemotaxis through regulation of F-actin polymerization at the pseudopods. Isoform ankyrin-iPLA2-1 and isoform ankyrin-iPLA2-2, which lack the catalytic domain, are probably involved in the negative regulation of iPLA2 activity. |
| Application Dilution | |
| WB | 1:300-5000 |
| IF(IHC-P) | 1:50-200 |
| IF(IHC-F) | 1:50-200 |
| IF(ICC) | 1:50-200 |
Frequently asked questions
Which applications is CaIPLA2 Polyclonal Antibody, PerCP Conjugated (bs-6709R-PerCP) validated for, and at what dilution?
bs-6709R-PerCP is validated for WB (1:300-5000); IF(IHC-P) (1:50-200); IF(IHC-F) (1:50-200); IF(ICC) (1:50-200). These are recommended starting dilutions; optimal dilutions should be determined by the end user.
How should bs-6709R-PerCP be stored?
Store at -20C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. Storage buffer: Aqueous buffered solution containing 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
What immunogen was used to raise CaIPLA2 Polyclonal Antibody, PerCP Conjugated (bs-6709R-PerCP)?
KLH conjugated synthetic peptide derived from human CaI-PLA2/PLA2G6
What are the excitation and emission wavelengths of the PerCP conjugate (bs-6709R-PerCP)?
PerCP on bs-6709R-PerCP: excitation / emission 482nm/677nm.